Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Macrogenics (MGNX) Revenue (2016 - 2025)

Macrogenics (MGNX) has disclosed Revenue for 14 consecutive years, with $41.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 3.07% to $41.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.5 million, a 185.28% increase, with the full-year FY2025 number at $149.5 million, changed 0.31% from a year prior.
  • Revenue was $41.2 million for Q4 2025 at Macrogenics, down from $72.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $73.1 million in Q4 2022 to a low of $3.3 million in Q2 2024.
  • A 5-year average of $25.8 million and a median of $16.9 million in 2021 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 85.33% in 2023, then soared 573.97% in 2025.
  • Macrogenics' Revenue stood at $14.1 million in 2021, then skyrocketed by 416.71% to $73.1 million in 2022, then plummeted by 85.33% to $10.7 million in 2023, then soared by 273.13% to $40.0 million in 2024, then increased by 3.07% to $41.2 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Revenue are $41.2 million (Q4 2025), $72.8 million (Q3 2025), and $22.2 million (Q2 2025).